CalciMedica’s Auxora Shows Promise in Acute Pancreatitis Trial
Company Announcements

CalciMedica’s Auxora Shows Promise in Acute Pancreatitis Trial

CalciMedica (CALC) just unveiled an announcement.

CalciMedica, Inc. announced positive results from its Phase 2b CARPO trial of Auxora for treating acute pancreatitis with systemic inflammatory response syndrome. The study met its objectives, showing a significant dose-response in reducing the time to solid food tolerance and severe organ failure. High and medium doses of Auxora led to a considerable decrease in hospital stay and risk of prolonged hospitalization, with a good safety profile indicated by the number of treatment-emergent serious adverse events. The company plans to present further data later this year and is moving forward with additional trials for Auxora in different medical conditions.

Find detailed analytics on CALC stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyCalciMedica price target lowered to $16 from $20 at H.C. Wainwright
TheFlyCalciMedica announces common stock offering, no amount given
TipRanks Auto-Generated NewsdeskCalciMedica’s Promising Phase 2b Trial Results for Auxora
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App